Author(s):
1. Habip Gedik:
Department of Infectious Disease and Clinical Microbiology, University of
Health Sciences and Ministry of Health, Bakirkoy Dr. Sadi Konuk Training and
Research Hospital, Istanbul, Turkey
2. Muge Sonmezisik:
Department of Infectious Disease and Clinical Microbiology, University of
Health Sciences and Ministry of Health, Bakirkoy Dr. Sadi Konuk Training and
Research Hospital, Istanbul, Turkey
Abstract:
We report two treatment-naïve cases, a 26-year-old female patient and a 59-year-old male patient who were followed up for chronic hepatitis B (CHB) at the department of Infectious Diseases and Clinical microbiology. A partial response subsequent to 12 months of Tenofovir Disoproksil (TDF) monotherapy presumably due to an antiviral-drug resistance was noted. A sustained viral response with TDF (245 mg) or Tenofovir Alafenamide (TAF, 25 mg) + Entecavir (ETV, 1 mg) combination therapy was observed after failure with TDF monotherapy. A combination therapy with TDF (245 mg) or TAF (25 mg) +ETV (1 mg) is efficacious in naïve patients with a partial response to TDF monotherapy.
Page(s):
550-552
DOI:
DOI not available
Published:
Journal: Journal of Pakistan Medical Association, Volume: 71, Issue: 2A, Year: 2021
Keywords:
Entecavir
,
Combination therapy
,
Chronic hepatitis B
,
Tenofovir
,
partial response
References:
References are not available for this document.
Citations
Citations are not available for this document.